Vaccination with trifunctional nanoparticles that address CD8+ dendritic cells inhibits growth of established melanoma

Nanomedicine

Volumn 11, Issue 20, 2016, Pages 2647-2662

  Shen, Limei ^a   Krauthäuser, Susanne ^b   Fischer, Karl ^c   Hobernik, Dominika ^a   Abassi, Yasmin ^a   Dzionek, Andrzej ^b   Nikolaev, Alexej ^a   Voltz, Nicole ^a   Diken, Mustafa ^a   Krummen, Mathias ^a   Montermann, Evelyn ^a   Tubbe, Ingrid ^a   Lorenz, Steffen ^a   Strand, Dennis ^a   Schild, Hansjörg ^a   Grabbe, Stephan ^a   Bros, Matthias ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b MILTENYI BIOTEC GMBH   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

CpG; CTL; DEC205; dendritic cell; IFN ; MDSC; nanoparticles; targeting; TNF ; tumor therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DEC205 ANTIBODY; DENDRITIC CELL VACCINE; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 1BETA; MAGNETIC NANOPARTICLE; NANOPARTICLE; OLIGONUCLEOTIDE; OVALBUMIN; OVALBUMIN CPG OLIGONUCLEOTIDE CONJUGATED NANOPARTICLE; OVALBUMIN CPG OLIGONUCLEOTIDE DEC205 ANTIBODY CONJUGATED NANOPARTICLE; OVALBUMIN DEC205 ANTIBODY CONJUGATED NANOPARTICLE; RECEPTOR ANTIBODY; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIBODY; CD8 ANTIGEN; CELL SURFACE RECEPTOR; DEC-205 RECEPTOR; DEXTRAN; FLUORESCENT DYE; LECTIN; LEUKOCYTE ANTIGEN; MAGNETITE NANOPARTICLE; MINOR HISTOCOMPATIBILITY ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BONE MARROW DERIVED DENDRITIC CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR VOLUME; VACCINATION; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; DENDRITIC CELL; EXPERIMENTAL MELANOMA; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SURFACE PROPERTY;

ANIMALS; ANTIBODIES; ANTIGENS, CD; CD8 ANTIGENS; CELL PROLIFERATION; CPG ISLANDS; DENDRITIC CELLS; DEXTRANS; FLUORESCENT DYES; HUMANS; IMMUNOTHERAPY; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MAGNETITE NANOPARTICLES; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MINOR HISTOCOMPATIBILITY ANTIGENS; OLIGONUCLEOTIDES; OVALBUMIN; RECEPTORS, CELL SURFACE; SURFACE PROPERTIES; TUMOR BURDEN; VACCINATION;

EID: 84990032221     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2016-0174     Document Type: Article

References (56)

1. Luke JJ, Callahan MK, Postow MA et al. Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 119(20), 3687-3695 (2013).
2. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next Curr. Opin. Immunol. 33, 23-35 (2015).
3. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
4. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol. Rev. 257(1), 56-71 (2014).
5. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
6. Eggermont AM. Can immuno-oncology offer a truly pantumour approach to therapy Ann. Oncol. 23(Suppl. 8), viii53-viii57 (2012).
7. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4(3), 328-332 (1998).
8. Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized Phase III trial of the DC study group of the DeCOG. ann. Oncol. 17(4), 563-570 (2006).
9. Gerritsen WR. The evolving role of immunotherapy in prostate cancer. ann. Oncol. 23(Suppl. 8), viii22-viii27 (2012).
10. Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ. Dendritic cell-based vaccines: barriers and opportunities. Future Oncol. 8(10), 1273-1299 (2012).
11. Morel PA, Turner MS. Dendritic cells and the maintenance of self-tolerance. Immunol. Res. 50(2), 124-129 (2011).
12. Joffre O, Nolte MA, Spörri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 227(1), 234-247 (2009).
13. Domínguez PM, Ardavín C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol. Rev. 234(1), 90-104 (2010).
14. den Haan JM, Lehar SM, Bevan MJ. CD8+ but not CD8-dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192(12), 1685-1696 (2000).
15. Tullett KM, Lahoud MH, Radford KJ. Harnessing human cross-presenting CLEC9A+XCR1+ dendritic cells for immunotherapy. Front. Immunol. 5, 239 (2014).
16. Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. J. Clin. Invest. 126(3), 799-808 (2016).
17. Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res. 25(8), 1815-1821 (2008).
18. Chanmee T, Ontong P, Konno K, Itano N. Tumorassociated macrophages as major players in the tumor microenvironment. Cancers (Basel) 6(3), 1670-1690 (2014).
19. Grainger JR, Askenase MH, Guimont-Desrochers F, da Fonseca DM, Belkaid Y. Contextual functions of antigenpresenting cells in the gastrointestinal tract. Immunol. Rev. 259(1), 75-87 (2014).
20. Heikenwalder M, Polymenidou M, Junt T et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10(2), 187-192 (2004).
21. Radford KJ, Caminschi I. New generation of dendritic cell vaccines. Hum. Vaccin. Immunother. 9(2), 259-264 (2013).
22. Hartung E, Becker M, Bachem A et al. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1. J. Immunol. 194(3), 1069-1079 (2015).
23. Irache JM, Salman HH, Gamazo C, Espuelas S. Mannosetargeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 5(6), 703-724 (2008).
24. Lahoud MH, Ahmet F, Zhang JG et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc. Natl Acad. Sci. USA 109(40), 16270-16275 (2012).
25. Miltenyi S, Müller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry 11(2), 231-238 (1990).
26. Bühler J, Gietzen S, Reuter A et al. Selective uptake of cylindrical poly(2-oxazoline) brush-antiDEC205 antibody-OVA antigen conjugates into DEC-positive dendritic cells and subsequent T-cell activation. Chemistry 20(39), 12405-12410 (2014).
27. Balkow S, Krux F, Loser K et al. Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naive T cells, and favors expansion of regulatory T cells. Blood 110(12), 3949-3958 (2007).
28. Kedl RM, Jordan M, Potter T et al. CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the absence of tumor-antigen vaccination. Proc. Natl Acad. Sci. USA 98(19), 10811-10816 (2001).
29. Ehlers S. DC-SIGN and mannosylated surface structures of Mycobacterium tuberculosis: A deceptive liaison. Eur. J. Cell Biol. 89(1), 95-101 (2010).
30. Shen L, Higuchi T, Tubbe I et al. a trifunctional dextranbased nanovaccine targets and activates murine dendritic cells, and induces potent cellular and humoral immune responses in vivo. PLoS ONE 8(12), e80904 (2013).
31. Ballas ZK, Krieg AM, Warren T et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167(9), 4878-4886 (2001).
32. Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74(1), 5-17 (2015).
33. Smith KA. Toward a molecular understanding of adaptive immunity: A chronology, Part III. Front. Immunol. 5, 29 (2014).
34. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138(2), 105-115 (2013).
35. Bonifaz L, Bonnyay D, Mahnke K et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196(12), 1627-1638 (2002).
36. Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine 6(4), 523-529 (2010).
37. Vieira OV, Botelho RJ, Grinstein S. Phagosome maturation: Aging gracefully. Biochem. J. 366(Pt 3), 689-704 (2002).
38. van Vliet SJ, den Dunnen J, Gringhuis SI, Geijtenbeek TB, van Kooyk Y. Innate signaling and regulation of dendritic cell immunity. Curr. Opin. Immunol. 19(4), 435-440 (2007).
39. Sheng KC, Kalkanidis M, Pouniotis DS et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur. J. Immunol. 38(2), 424-436 (2008).
40. Kronin V, Süss G, Winkel K, Shortman K. The regulation of T cell responses by a subpopulation of CD8+DEC205+ murine dendritic cells. adv. Exp. Med. Biol. 417, 239-248 (1997).
41. Dudziak D, Kamphorst AO, Heidkamp GF et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315(5808), 107-111 (2007).
42. Tappertzhofen K, Bednarczyk M, Koynov K et al. Toward anticancer immunotherapeutics: well-defined polymer-antibody conjugates for selective dendritic cell targeting. Macromol. Biosci. 14(10), 1444-1457 (2014).
43. Heit A, Huster KM, Schmitz F et al. CpG-DNA aided crosspriming by cross-presenting B cells. J. Immunol. 172(3), 1501-1507 (2004).
44. Shirota H, Klinman DM. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev. Vaccines 13(2), 299-312 (2014).
45. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol. Rev. 220, 251-269 (2007).
46. Duan X, Li Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small 9(9-10), 1521-1532 (2013).
47. Amoozgar Z, Goldberg MS. Targeting myeloid cells using nanoparticles to improve cancer immunotherapy. adv. Drug Deliv. Rev. 91, 38-51 (2015).
48. Patel PC, Giljohann DA, Daniel WL et al. Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. Bioconjug. Chem. 21(12), 2250-2256 (2010).
49. Kreutz M, Giquel B, Hu Q et al. antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity. PLoS ONE 7(7), e40208 (2012).
50. Tenzer S, Docter D, Kuharev J et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8(10), 772-781 (2013).
51. Molino NM, Anderson AK, Nelson EL, Wang SW. Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation. aCS Nano. 7(11), 9743-9752 (2013).
52. Hamdy S, Haddadi A, Shayeganpour A, Samuel J, Lavasanifar A. activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles. Pharm. Res. 28(9), 2288-2301 (2011).
53. Mills CD. M1 and M2 macrophages: oracles of health and disease. Crit. Rev. Immunol. 32(6), 463-488 (2012).
54. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloidderived suppressor cells. J. Immunol. 188(4), 1592-1599 (2012).
55. Joshi MD, Unger WJ, Storm G, van Kooyk Y, Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate carriers. J. Control Release 161(1), 25-37 (2012).
56. Castle JC, Kreiter S, Diekmann J et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72(5), 1081-1091 (2012).